Clinical Trial Update: Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial comparing daptomycin with an active comparator in acute hematogenous osteomyelitis has completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematogenous Osteomyelitis

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Acute Hematogenous Osteomyelitis | Phase 3 | Status: COMPLETED | Results posted: 2017-06-23